

Alzheimer's Disease Anti-inflammatory Prevention Trial – Follow-up Study
Introduction Letter for Participant

Dear <<Participant Name>>,

We are happy to tell you that we are going to begin a new phase of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). As you recall, as part of ADAPT you were assigned to receive one of three ADAPT study drugs several years ago: celecoxib/Celebrex®, naproxen sodium/Aleve®, or a placebo. These study drugs were stopped for all participants in December of 2004.

We have not been in contact with ADAPT participants since 2006. Now, three years later, we have new funding that makes it possible for us to connect with our participants once again to learn about their current health and memory abilities. These new contacts with ADAPT participants will provide important information about any long-term effects of the ADAPT treatments that were stopped in 2004.

We plan to call you in a few weeks to explain more about this phase of ADAPT. We will be glad to answer any questions you may have when we call. If you are willing to talk with us, we will also ask you to answer a few questions to test your memory and concentration abilities and we will ask about your current health. After these phone contacts, we will invite some participants to visit with us in-person for more examination and testing, just as we did in the earlier years of ADAPT.

This work will be very important. We hope you will accept our invitation to join once again in ADAPT. We look forward to talking with you soon.

Sincerely,

Field Site Director

Field Site Nurse Coordinator
